GB268

DRUG2 trials

Sponsors

Genor Biopharma Co., Ltd., Eddingpharm (Zhuhai) Co., Ltd.

Conditions

Breast Cancer (Locally Advanced or Metastatic)Solid Tumor Cancer

Phase 1

A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors

Not yet recruitingNCT06934616

Genor Biopharma Co., Ltd.Solid Tumor Cancer

Start: 2025-04-24End: 2028-03-31Target: 330Updated: 2025-04-30

GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)

Not yet recruitingNCT07738341

Eddingpharm (Zhuhai) Co., Ltd.Breast Cancer (Locally Advanced or Metastatic)

Start: 2026-08-01End: 2030-08-01Target: 270Updated: 2026-07-31